Clinical Trials Using Niraparib Tosylate Monohydrate
Clinical trials are research studies that involve people. The clinical trials on this list are studying Niraparib Tosylate Monohydrate. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Niraparib, Dostarlimab, and Radiation Therapy for the Treatment of Metastatic Pancreatic Cancer
This phase II trial investigates how well niraparib, dostarlimab, and radiation therapy work in treating patients with pancreatic cancer that has spread to other places in the body (metastatic). Niraparib is a type of drug called a “PARP inhibitor”, which blocks DNA (the genetic material of cells) damage from being repaired or may prevent damage from occurring in the first place. In cancer treatment, inhibiting PARP may help kill tumor cells by not allowing the tumor cells to repair its DNA damage or prevent DNA damage from occurring. Dostarlimab is a type of antibody (a protein that attaches to other cells to fight off infection) that is believed to work by attaching to a protein called PD-1 on T cells. This PD-1 protein controls parts of the immune system (the system in the body that fights off infections and diseases) by shutting down certain immune responses responsible for recognizing and destroying tumor cells. Dostarlimab may work by inhibiting the PD-1 protein, thus allowing immune cells to recognize and destroy tumor cells. Radiation therapy uses high energy protons to kill tumor cells and shrink tumors. Giving niraparib, dostarlimab, and radiation therapy may help treat patients with pancreatic cancer.
Location: 4 locations
Niraparib and Tumor-Treating Fields for the Treatment of Recurrent Glioblastoma
This phase II trial evaluates the safety and effectiveness of an investigational drug called niraparib in combination with tumor-treating fields for the treatment of patients with glioblastoma that has come back after a period of improvement (recurrence). Niraparib makes it harder for tumor cells to repair their DNA (the instructions inside the tumor cell that make it grow), which can lead to the death of tumor cells. Electric forces called tumor-treating fields may disrupt the growth of tumor cells. These tumor-treating fields are given to patients using a device called Optune. Giving niraparib and tumor-treating fields together may work better than the individual use of each intervention for the treatment of patients with recurrent glioblastoma.
Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania
Niraparib before Surgery in Treating Patients with High Risk Localized Prostate Cancer and DNA Damage Response Defects
This phase II trial studies how well niraparib, when given before surgery, works in treating patients with high risk prostate cancer that has not spread to other parts of the body (localized) and alterations in deoxyribonucleic acid (DNA) repair pathways. Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California
Abemaciclib and Niraparib before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer
This phase I trial tests the side effects and best dose of abemaciclib and niraparib in treating patients with breast cancer that is positive for estrogen or progesterone receptors (hormone receptor positive [HR+]) and HER2 negative. Abemaciclib may stop the growth of tumor cells by blocking certain proteins called cyclin-dependent kinases, which are needed for cell growth. PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as niraparib, can keep PARP from working so tumor cells can't repair themselves and grow. Giving abemaciclib and niraparib together before surgery may make the tumor smaller.
Location: OHSU Knight Cancer Institute, Portland, Oregon
Abiraterone Acetate, Prednisone, Leuprolide, Niraparib, and Stereotactic Body Radiotherapy for the Treatment of High Risk or Node Positive Prostate Cancer, The ASCLEPIuS Trial
This phase I / II trial investigates the best dose of niraparib and how well it works when given together with abiraterone acetate, prednisone, leuprolide, and stereotactic body radiotherapy in treating patients with high risk or node positive prostate cancer. PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as niraparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Abiraterone acetate and leuprolide may fight prostate cancer by lowering the amount of testosterone made by the body. Anti-inflammatory drugs, such as prednisone lower the body’s immune response and are used with other drugs in the treatment of some types of cancer. Stereotactic body radiotherapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving niraparib together with abiraterone acetate, prednisone, leuprolide and stereotactic body radiotherapy may kill more tumor cells.
Location: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan